Hiroyuki Ueda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hiroyuki Ueda has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Bruce A. Julian
Department of Microbiology, University of Alabama at Birmingham, 845 19th Street South, BBRB 762, Birmingham, AL 35294, USA ; Department of Medicine, University of Alabama at Birmingham, 845 19th Street South, Birmingham, AL 35294, USA
1 shared publication- Christopher Douglas Willey
The University of Alabama at Birmingham
1 shared publication - Colin Reily
Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA
1 shared publication - Jan Novak
Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USA
1 shared publication Jiri Mestecky
Department of Microbiology, University of Alabama at Birmingham, 845 19th Street South, BBRB 762, Birmingham, AL 35294, USA ; Department of Medicine, University of Alabama at Birmingham, 845 19th Street South, Birmingham, AL 35294, USA
1 shared publicationZhi-Qiang Huang
Department of Microbiology, University of Alabama at Birmingham, 845 19th Street South, BBRB 762, Birmingham, AL 35294, USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2014
- Published by Wiley in Journal of Immunology Research
- Vol. 2014, 1-10
Cellular Signaling and Production of Galactose-Deficient IgA1 in IgA Nephropathy, an Autoimmune Disease
Immunoglobulin A (IgA) nephropathy (IgAN), the leading cause of primary glomerulonephritis, is characterized by IgA1-containing immunodeposits in the glomeruli. IgAN is a chronic disease, with up to 40% of patients progressing to end-stage renal disease, with no disease-specific treatment. Multiple studies of the origin of the glomerular immunodeposits have linked elevated circulating levels of aberrantly glycosylated IgA1 (galactose-deficient in someO-glycans; Gd-IgA1) with formation of nephritogenic Gd-IgA1-containing immune complexes. Gd-IgA1 is recognized as an autoantigen in susceptible individuals by anti-glycan autoantibodies, resulting in immune complexes that may ultimately deposit in the kidney and induce glomerular injury. Genetic studies have revealed that an elevated level of Gd-IgA1 in the circulation of IgAN patients is a hereditable trait. Moreover, recent genome-wide association studies have identified several immunity-related loci that associated with IgAN. Production of Gd-IgA1 by IgA1-secreting cells of IgAN patients has been attributed to abnormal expression and activity of several key glycosyltransferases. Substantial evidence is emerging that abnormal signaling in IgA1-producing cells is related to the production of Gd-IgA1. As Gd-IgA1 is the key autoantigen in IgAN, understanding the genetic, biochemical, and environmental aspects of the abnormal signaling in IgA1-producing cells will provide insight into possible targets for future disease-specific therapy.
- 1 January 2014
- Published by Wiley in Journal of Immunology Research
- Vol. 2014, 1-10
Open AccessCellular Signaling and Production of Galactose-Deficient IgA1 in IgA Nephropathy, an Autoimmune Disease
Immunoglobulin A (IgA) nephropathy (IgAN), the leading cause of primary glomerulonephritis, is characterized by IgA1-containing immunodeposits in the glomeruli. IgAN is a chronic disease, with up to 40% of patients progressing to end-stage renal disease, with no disease-specific treatment. Multiple studies of the origin of the glomerular immunodeposits have linked elevated circulating levels of aberrantly glycosylated IgA1 (galactose-deficient in someO-glycans; Gd-IgA1) with formation of nephritogenic Gd-IgA1-containing immune complexes. Gd-IgA1 is recognized as an autoantigen in susceptible individuals by anti-glycan autoantibodies, resulting in immune complexes that may ultimately deposit in the kidney and induce glomerular injury. Genetic studies have revealed that an elevated level of Gd-IgA1 in the circulation of IgAN patients is a hereditable trait. Moreover, recent genome-wide association studies have identified several immunity-related loci that associated with IgAN. Production of Gd-IgA1 by IgA1-secreting cells of IgAN patients has been attributed to abnormal expression and activity of several key glycosyltransferases. Substantial evidence is emerging that abnormal signaling in IgA1-producing cells is related to the production of Gd-IgA1. As Gd-IgA1 is the key autoantigen in IgAN, understanding the genetic, biochemical, and environmental aspects of the abnormal signaling in IgA1-producing cells will provide insight into possible targets for future disease-specific therapy.